Nodular lymphocyte predominant Hodgkin lymphoma digital illustration

Nodular lymphocyte predominant Hodgkin lymphoma Save


ICD-10 code: C81.0

Chapter: Neoplasms

Nodular Lymphocyte Predominant Hodgkin Lymphoma: Understanding a Rare Form of Cancer

Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) is a rare subtype of Hodgkin Lymphoma (HL). It is characterized by the presence of large, popcorn-shaped cells known as lymphocyte-predominant (LP) cells. While it accounts for only 5% of all HL cases, it is important to understand the nature of this disease.

Symptoms: NLPHL usually presents with painless swelling of lymph nodes, most commonly in the neck, armpit or groin. Other symptoms may include fever, night sweats, fatigue, weight loss, and itching.

Diagnosis: NLPHL diagnosis requires biopsy of an enlarged lymph node. Pathologists will then examine the cells under a microscope to identify the presence of LP cells. Additional tests may include imaging studies such as CT scan or PET scan.

Treatment: Treatment for NLPHL varies depending on the stage and extent of the disease. In early stages, radiation therapy may be the primary mode of treatment. For more advanced stages, chemotherapy may be necessary. In some cases, a combination of radiation and chemotherapy may be used.

  1. Radiotherapy: This is the most common treatment for early-stage NLPHL. It involves the use of high-energy radiation to target and destroy cancer cells. Depending on the extent of the disease, radiation therapy may be administered for several weeks.
  2. Chemotherapy: This involves the use of drugs to kill cancer cells. Chemotherapy is usually administered intravenously (IV) in cycles over several months.
  3. Watchful Waiting: In some cases, doctors may recommend a "watchful waiting" approach for early-stage NLPHL. This involves monitoring the disease closely with regular check-ups and imaging studies. Treatment is only initiated if the disease progresses.

Prognosis: The prognosis for NLPHL is generally good. It is a slow-growing cancer and tends to be less aggressive than other forms of HL. The five-year survival rate for NLPHL is around 90%.

Conclusion: While NLPHL is a rare form of HL, it is important to be aware of its existence. Early diagnosis and treatment can lead to a favorable prognosis. If you experience any symptoms such as painless swelling of lymph nodes, fever, or night sweats, it is important to consult with your doctor.